Toripalimab (Loqtorzi)
Revision as of 14:14, 18 November 2023 by Jwarner (talk | contribs) (Jwarner moved page Toripalimab (Loqtorz) to Toripalimab (Loqtorzi): Brand name not spelled right)
Mechanism of action
From the NCI Drug Dictionary: A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, toripalimab binds to PD-1 and inhibits the binding of PD-1 to its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
Diseases for which it is established
Diseases for which it is used
- Esophageal squamous cell carcinoma
- Melanoma
- Non-small cell lung cancer, nonsquamous
- Non-small cell lung cancer, squamous
- Urothelial carcinoma
History of changes in FDA indication
- 2023-10-27: Approved with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC). (Based on JUPITER-02)
- 2023-10-27: Approved as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy. (Based on POLARIS-02)
History of changes in NMPA indication
- 2018-12-17: Initial approval
Also known as
- Code names: JS-001, TAB-001
- Generic name: teriprolizumab, toripalimab-tpzi
- Brand name: Loqtorz, Tuoyi
Categories:
- Drugs
- Intravenous medications
- Anti-PD-1 antibodies
- Esophageal squamous cell carcinoma medications
- Melanoma medications
- Nasopharyngeal carcinoma medications
- Non-small cell lung cancer, nonsquamous medications
- Non-small cell lung cancer, squamous medications
- Urothelial carcinoma medications
- NMPA approved in 2018
- FDA approved in 2023